Publications

Manuscripts

View manuscript (web link)

Monaghan KA, et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia (advance online publication July 26, 2011)

View manuscript (web link)

Tyner JW, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood June 2010; 115(25): 5232-5240 (First Edition Paper published online April 12, 2010)

View manuscript (web link)

Burns CJ, et al. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg Med Chem Lett 2009 Oct; 19(20): 5887-5892

View manuscript (pdf)

Pardanani A, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23: 1441-1445

Posters and Abstracts

View poster (pdf)

Pardanani A, et al. Safety and Efficacy of CYT387, a JAK1 and JAK2 Inhibitor for the Treatment of Myelofibrosis. 2011 American Society of Hematology (ASH) Annual Meeting, Poster #3849

View poster (pdf)

Pardanani AD, et al. Safety and efficacy of CYT387, a JAK 1/2 inhibitor, for the treatment of myelofibrosis (interim results). 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, Poster

View abstract (web link)

Pardanani A, et al. A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates in Anemia, Splenomegaly, and Constitutional Symptoms. 2010 American Society of Hematology (ASH) Annual Meeting, Abstract

View poster (pdf)

Fantino E, et al. Preclinical characterization of CYT387: a potent and selective dual inhibitor of JAK1/JAK2. 2010 European School of Haematology (ESH) International Conference on Myeloproliferative Neoplasms, Poster

View abstract (pdf)

Burns CJ. A novel, potent and selective dual inhibitor of JAK1 and JAK2 for treatment of myeloproliferative neoplasms. 2010 New Directions in Leukaemia Research (NDLR), Abstract

View poster (pdf)

Fantino E, Burns CJ, et al. A novel, potent and selective dual inhibitor of JAK1 and JAK2 for treatment of myeloproliferative neoplasms and cancer. 2010 Lorne Cancer Conference, Poster

View abstract (web link)

Bumm TG, et al. Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD. 2008 ASH Annual Meeting, Abstract 856

View abstract (web link)

Wilks A, et al. A novel JAK2 inhibitor for the treatment of myeloproliferative disorders. 2008 American Association for Cancer Research (AACR) Annual Meeting, Abstract 4880

link to PDF file

link to external website